Genome landscapes of major melanoma subtypes are heavily mutated and harbor critical genetic alterations in several genes controlling cancer initiation and progression, such as the BRAF, NRAS, NF1, TP53, and CDKN2A ones, thus conferring subtype-dependent mutagen signatures and therapeutic targets on melanoma [1,19,20]. This evidence concerns the gene TP53 and melanoma.